Sign in

Herbert Irving Comprehensive Cancer Center

@columbiacancer.bsky.social
382 followers 15 following 80 posts

Updates on innovations in #cancer research, prevention, care, and education from the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center and NewYork-Presbyterian.

PostsRepliesMedia
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 21/07/2026
As cases of uterine cancer rise, a new non-invasive test being studied in clinical trials at @columbiamed.bsky.social could offer a simpler, more comfortable way to diagnose the disease and help some women avoid an invasive biopsy. Here's what to know: www.cancer.columbia.edu/news/new-swa...
cancer.columbia.edu
New Swab Test for Endometrial Cancer Could Offer Easier Diagnosis
A non-invasive test being studied in clinical trials at Columbia and 11 other medical centers may soon offer a simpler, more comfortable way to diagnose endometrial (uterine) cancer.
010
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 29/05/2026
Happening today at 4:57 PM CDT: Results from NEXUS-01, a phase 1 study of LY4052031 from Alexander Wei, MD will be discussed in an Oral Abstract Session on Genitourinary Cancer—Kidney and Bladder. Read the abstract - asco.org/abstracts-pr...
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 29/05/2026
Abstract now live! Research from Columbia author Catherine Shu, MD will be presented in an Oral Abstract on Lung Cancer—Non-Small Cell Metastatic. View more- asco.org/abstracts-pr...
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 29/05/2026
We are headed to #ASCO26! ✈️🔬Follow along with us May 29 - June 2 as we share HICCC research being presented at ASCO's annual meeting! @columbiamed.bsky.social
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 22/05/2026
Breakthroughs in cancer research don’t usually begin with multi-million-dollar grants — they start with one bold idea. See how pilot funding has helped HICCC researchers take risks to shape the future of cancer treatments. #NationalCancerResearchMonth www.cancer.columbia.edu/news/idea-im...
cancer.columbia.edu
From Idea to Impact: How Pilot Funding Fuels Cancer Discovery
Early-stage, strategic investments help researchers test bold ideas, creating momentum and new directions in cancer research.
010
Reposted by Herbert Irving Comprehensive Cancer Center
thedoctorisvin.bsky.social @thedoctorisvin.bsky.social · 19/05/2026
Great write-up from @columbiacancer.bsky.social "A cellular wrong turn in blood cancer” on our paper from @cohesinlab.bsky.social published in @bloodjournal.bsky.social . 🔑Key point: STAG2 doesn’t change how much GATA1 there is—it changes where it can act. www.cancer.columbia.edu/news/cellula...
cancer.columbia.edu
A cellular wrong turn in blood cancer
A new study reveals how disrupted DNA navigation leads to impaired red blood cell development in myelodysplastic syndrome
022
Reposted by Herbert Irving Comprehensive Cancer Center
KenOliveLab @kenolivelab.bsky.social · 20/04/2026
Super proud of my postdoc, Alvaro Curiel-Garcia @alvarocuriel.bsky.social for his Rising Star lecture at #AACR26. Alvaro has a Nature Genetics cofirst author paper in press, and another 1st author manuscript that is in revision, also at Nature Genetics. He's on the job market folks!
061
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 17/04/2026
Millions of women are finding out they have dense breasts, but what to do next still leaves many uncertain. In this Q&A, Julia McGuinness & Elena Elkin explain why breast density alone isn’t enough to guide breast cancer screening decisions: www.cancer.columbia.edu/news/beyond-...
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 17/04/2026
Major Symposium: RAS Inhibitors, Mechanisms of Resistance, and Drug Combinations BMAL2 is a KRAS-driven master regulator of hypoxic adaptation and EMT in pancreatic ductal adenocarcinoma Presenter: Alvaro Curiel Garcia, PhD www.abstractsonline.com/pp8/#!/21436...
abstractsonline.com
Program Planner
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 17/04/2026
Major Symposium: Optimizing the antigen sensitivity and functional persistence of CAR T cells Presenter: Michel Sadelain, MD, PhD www.abstractsonline.com/pp8/#!/21436...
abstractsonline.com
Program Planner
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 17/04/2026
Clinical Trials Plenary Session: First data disclosure of the Phase I trial of the first in class combination of WEE1 inhibitor zedoresertib with PKMYT1 inhibitor lunresertib Columbia author: Ryan H. Moy, MD www.abstractsonline.com/pp8/#!/21436...
abstractsonline.com
Program Planner
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 17/04/2026
HICCC is AACR-bound! ✈️🔬 Take a look at our @theaacr.bsky.social 2026 roundup and mark your calendar: our research will be shared in 40+ sessions and presentations. Check out our major symposia highlights from this year’s meeting, below: www.cancer.columbia.edu/news/roundup...
cancer.columbia.edu
Roundup: HICCC at AACR 2026
HICCC researchers will present updates across key cancer research topics at this year's American Association for Cancer Research annual meeting.
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 02/03/2026
Julia McGuinness, MD has been awarded a $100,000 @preventcancer.org grant to study whether weight-loss treatments lead to mammogram changes that signal lower breast cancer risk. 👏 Learn more. preventcancer.org/news/prevent...
010
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 22/02/2026
Big changes to U.S. nutrition guidance are here with the HHS new “inverted” food pyramid. For Cancer Prevention Month, @columbiamed.bsky.social dietitian Sabrina Oliver breaks down how to view the guidelines through a cancer-prevention lens. 🥦🥩 www.cancer.columbia.edu/news/does-ne...
cancer.columbia.edu
Does the New Food Pyramid Match What We Know About Cancer Prevention?
Oncology dietician Sabrina Oliver reflects on the new “inverted” food pyramid and how people can interpret the guidelines through a cancer-prevention lens.
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 20/02/2026
‼️After a decade+ of research, @columbiamed.bsky.social scientists led by Wei Gu have discovered the natural mechanism behind a novel form of cell death called ferroptosis. Read about this work in @cellpress.bsky.social www.cancer.columbia.edu/news/ironing...
cancer.columbia.edu
Ironing Out Cancer
Columbia researchers have discovered the natural mechanism behind a type of cell death called ferroptosis - solving a longstanding puzzle in cell biology.
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 18/02/2026
New research led by Andrea Califano, Dr, unveils a framework to decode hundreds of thousands of previously “uninterpretable” cancer mutations— helping clinicians prioritize more effective treatments and avoid unnecessary ones. @biohub.org 🔗 www.cancer.columbia.edu/news/turning...
021
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 10/02/2026
Sarcoma is rare, but inequities in life-saving care are widespread in underserved communities. Read how Wakenda Tyler, MD, is pushing the field to confront disparities, like higher amputation and mortality rates. #BlackHistoryMonth @columbiamed.bsky.social www.cancer.columbia.edu/news/wakenda...
cancer.columbia.edu
Wakenda Tyler, MD: Bringing Health Equity into Sarcoma Care
In honor of Black History Month, we spoke with Dr. Tyler about why she thinks disparities research should be a priority in sarcoma care.
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 06/02/2026
💭 Do GLP-1s raise, lower, or not affect cancer risk? As GLP-1 drugs surge in popularity, so have questions about their safety, especially around cancer. Based on current evidence, the answer is reassuring and increasingly hopeful. ⤵️ www.cancer.columbia.edu/news/glp-1-w...
cancer.columbia.edu
GLP-1 Weight Loss Drugs and Cancer: Is There a Link?
GLP-1 weight-loss medications have changed how doctors treat obesity- here’s what we know about their impact on cancer.
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 30/01/2026
A national clinical trial open at @columbiamed.bsky.social is testing a new precision medicine approach developed by Rob Wechsler-Reya, PhD- directly testing how each patient’s tumor cells respond to different drugs, rather than testing genetics alone. → www.cancer.columbia.edu/news/q-testi...
cancer.columbia.edu
Testing Drug Responses, Not Just Genes: A New Functional Precision Medicine Trial Comes to Columbia
We spoke with Rob Wechsler-Reya, PhD, about a novel functional precision medicine approach that he developed, which is being tested in a national clinical trial now opening at Columbia.
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 06/01/2026
The 2025 issue of Pathways to a Cure is here! See how HICCC is driving breakthroughs in cell therapy, AI precision prevention, and early-onset cancers—while expanding access to world-class care at Columbia. Read now ⬇️ pubs.cancer.columbia.edu/reports/2025...
pubs.cancer.columbia.edu
2025 Annual Report
The Herbert Irving Comprehensive Cancer Center earned renewed Comprehensive Cancer Center designation from the National Cancer Institute for 2025–2030, with $27 million in funding to strengthen cancer...
010
Reposted by Herbert Irving Comprehensive Cancer Center
Nature Biotechnology @natbiotech.nature.com · 05/01/2026
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma - @columbiacancer.bsky.social go.nature.com/496Ins7
go.nature.com
Engineering bispecific exosome activators of T cells to target immune checkpoint inhibitor-resistant metastatic melanoma - Nature Biotechnology
Engineered inhalable exosomes deliver a bispecific T cell activator to pembrolizumab-resistant metastatic melanoma.
151
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 05/12/2025
HICCC is presenting at #ASH2025! Follow along for highlights on research from Columbia at this year’s American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando. ↘️Be sure to tag us to be promoted! View more: mailchi.mp/cumc/hiccc-w...
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 22/07/2025
The first FDA-approved liquid biopsy test for cancer screening is here - and raising big questions about how it could transform cancer care. HICCC’s Dr. Chin Hur weighs in. More in this Q&A 👉 cancer.columbia.edu/news/what-kn...
cancer.columbia.edu
What to Know About Liquid Biopsies for Cancer
Liquid biopsies have the potential to transform cancer care. We asked Dr. Chin Hur how these tests fit into the future of personalized cancer screening, now that one has FDA approval.
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 17/07/2025
The Spring/Summer issue of Accelerations is here! We're spotlighting momentum— discover what's next in cancer research, breakthroughs in drug discovery, and progress in pancreatic cancer. Read the issue below. hiccc-accelerations.onpubli.com/Spring-Summe...
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 09/07/2025
Getting through the blood-brain barrier remains a huge challenge in brain tumor treatment. Read how HICCC researchers Elisa Konofagou & Stergios Zacharoulis are using #soundwaves to open it just long enough to deliver therapy. engineering.columbia.edu/about/news/t...
020
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 08/07/2025
Uterine cancer is one of the few cancers with rising incidence and mortality. A new @columbiamed.bsky.social study led by HICCC’s Jason D. Wright projects a sharp increase over the next 30 years—disproportionately impacting Black women. Read more: www.cuimc.columbia.edu/news/uterine...
cuimc.columbia.edu
Uterine Cancer Rates Predicted to Rise, Especially Among Black Women
A new study forecasts a substantial rise in uterine cancer cases and deaths over the next three decades, with a disproportionate impact on Black women.
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 25/06/2025
Last week, we celebrated the official launch of the Center for Innovation in Imaging Biomarkers and Integrated Diagnostics (CIMBID) at Columbia. @columbiamed.bsky.social Catch the highlights and recordings below. @columbiaimaging.bsky.social columbiaradiology.org/news/columbi...
000
Reposted by Herbert Irving Comprehensive Cancer Center
Irving Institute for Cancer Dynamics @cancerdynamics.bsky.social · 23/06/2025
Today marks Day 1 of the second cohort of the 2025 IICD Intensive Workshop. We’re thrilled to welcome a new group of graduate students and postdocs for a week of immersive learning! #CancerResearch #STEMeducation @elhamazizi.bsky.social @columbiamed.bsky.social @columbiacancer.bsky.social
2025 IICD Intensive Workshop first day in classroom
031
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 09/06/2025
Tattoos last forever-but do they come with health risks that stick around just as long? 💭 HICCC's Dr. Mariam El-Ashmawy breaks down what early research shows —and what you can do to protect your skin with or without tattoos. www.cancer.columbia.edu/news/tattoos...
cancer.columbia.edu
Tattoos and Skin Cancer: A Cause for Concern?
Mariam El-Ashmawy, MD, PhD, shares what you need to know about tattoos and skin cancer—and how to protect your skin for the long run.
000
Reposted by Herbert Irving Comprehensive Cancer Center
Irving Institute for Cancer Dynamics @cancerdynamics.bsky.social · 04/06/2025
The SRP interns had a great seminar with Dr. @brentstockwell.bsky.social Thank you, Dr. Stockwell, for sharing your career path and research with our summer interns! 🔬✨ #CancerResearch #STEMeducation #IICDSR #SummerInternship @columbiacancer.bsky.social
Brent Stockwell presenting to SRP
031
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 05/06/2025
Highlights from HICCC's 3rd Annual Clinical Trials Day at @columbiamed.bsky.social 🏥👏 Thank you to everyone who joined us last week to learn about the urgent need for broader participation in #ClinicalTrials
010
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 03/06/2025
6/3, 10:45 AM EST/9:45 AM CDT , A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000 (NCT04511013). Authors: Vadim Spektor. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 03/06/2025
6/3, 10:45 AM EST/ 9:45 AM, Does the Road to Cure Myeloma End with Minimal Residual Disease?. Discussant: Suzanne Lentzsch, MD, PhD. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 03/06/2025
View today's final HICCC #ASCO2025 daily roundup, below!
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 02/06/2025
6/2, 8:00 AM CDT, Efficacy and safety of dordaviprone (ONC201) in prospective clinical trials of adult and pediatric recurrent H3 K27M-mutant diffuse glioma patients. Author: Aya Haggiagi meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
010
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 02/06/2025
6/2, 9:45 AM CDT, A first-in-human study of DYP688, an antibody drug conjugate delivering a direct Gq/11 inhibitor, in patients with metastatic uveal melanoma (MUM) and other GNAQ/11 mutant melanomas. Author: Alexander Wei. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
100
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 02/06/2025
6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial. Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 02/06/2025
6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + bortezomib (BTZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): First results from the LINKER-MM2 trial. Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 02/06/2025
6/2, 8:00 AM CDT, Linvoseltamab (LINVO) + carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): Initial results from the LINKER-MM2 trial. Author: Rajshekhar Chakraborty. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
100
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 02/06/2025
View today's HICCC #ASCO2025 daily roundup, below!
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 31/05/2025
5/31, 1:15 PM CDT. Phase I/Ib study of INAVO alone and in combination with endocrine therapy ± palbociclib in patients (pts) with PIK3CA-mutated, hormone receptor–positive, HER2-negative locally advanced/metastatic breast cancer. Author: Melissa Accordino meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 31/05/2025
5/31, 3:00 PM CDT. Phase 1 clinical update of IMA203, an autologous TCR-T targeting PRAME in patients with PD1 refractory metastatic melanoma. Author: Ran Reshef meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
100
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 31/05/2025
5/31, 3:00 PM CDT. Use of lucicebtide (ST101) in glioblastoma patients by antagonism of C/EBPβ-dependent mesenchymal cell transition and immunosuppressive M2 macrophage polarization. Presenter: Fabio Massaiti Iwamoto meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
100
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 31/05/2025
5/31, 8:00 AM CDT, Association between allostatic load and breast radiomic features among diverse women undergoing screening mammography. Presenter: Sara Wallam meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
100
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 31/05/2025
View today's HICCC #ASCO25 daily research roundup, below!
120
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 30/05/2025
5/30, 2:45 PM , A phase 2 study of pemigatinib for pre-treated glioblastoma or other gliomas with activating FGFR1-3 alterations: Results from FIGHT-209. Author: Andrew Lassman. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
000
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 30/05/2025
5/30, 2:45 PM , A phase 1 study of KITE-363 anti-CD19/CD20 chimeric antigen receptor (CAR) T-cell therapy in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL). Author: Ran Reshef. meetings.asco.org/2025-asco-an...
meetings.asco.org
Program Guide – ASCO Meeting Program Guide
110
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 30/05/2025
View today's HICCC #ASCO2025 daily roundup, below!
100
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 29/05/2025
Headed to #ASCO2025 ?! 🔬✈️ Stay tuned for daily HICCC sessions, spotlight lectures, and late breaking research at @ascocancer.bsky.social ! Be sure to add our sessions to your meeting planner, and tag us to be featured! 📸 meetings.asco.org/meetings/202...
031
Herbert Irving Comprehensive Cancer Center @columbiacancer.bsky.social · 21/05/2025
Nearly everything we know about cancer started in a clinical trial. But what are clinical trials really like? 💭 🔬 Read on for answers to more common questions—and misconceptions—about cancer #clinicaltrials www.cancer.columbia.edu/news/answeri...
cancer.columbia.edu
Answering 10 Commonly Asked Questions About Cancer Clinical Trials
We answer 10 of the most common—and often misunderstood—questions about how cancer clinical trials work, who they’re for, and why they matter.
000